Modern medicine has given us countless methods of understanding, measuring and managing such metrics of our health such as temperature, weight, cholesterol, etc. And yet a simple, non-invasive method for measuring and quantifying the health of our brains has eluded us. Being unable to accurately measure how a brain functions hinders doctors’ ability to diagnose and treat mental and psychiatric disorders.
Major Depressive Disorder (MDD) has been identified as the leading and most costly mental disorder, accounting for 33% of the total cost of brain disorders, and equal to 1% of the total economy of Europe (GDP). Each year, about 7% of the population suffer from MDD in Europe, equivalent to 52.98 million people. In the US, MDD is the leading cause of disability for ages 15 to 44.3, and affects more than 16 million American adults, or about 6.7% of the U.S. population age 18 and older in a given year.
The current methods of treatment are prescribed through trial and error with patients rarely receiving the ‘right’ treatment from day one. This reduces response rates and delays remission, which has a heavy impact on the individual’s quality of life.
Elminda has developed the “BNA-PREDICT” tool which predicts responsiveness to antidepressants and transcranial magnetic stimulation (TMS) treatment, and thus dramatically reduces time from diagnosis to amelioration of symptoms for MDD patients. PREDICT determines personalized treatments for MDD patients based on validated electroencephalogram and event-related potential brain-related biomarkers. The tool is expected to improve response rates, quality of life and results in significant savings for the healthcare systems.
PREDICT project is funded through Horizon 2020’s Small and Medium-sized Enterprise (SME) instrument, which targets high potential SMEs with groundbreaking products that have the potential to profoundly impact the EU economy and global healthcare.
The two-year grant will contribute to the following activities: (i) Finalize design and development of the PREDICT technology; (ii) Perform a clinical validation for the technology in a multi-center clinical study in leading medical centers in Europe; (iii) Advance the PREDICT tool to commercialisation in Europe by revising the IP portfolio, prepare for CE Marking of the PREDICT system and first reimbursement requests.
The Predict Team
The BNA-PREDICT project’s multi-disciplinary team includes accomplished neuroscientists, SW engineers, IP and regulatory experts, and business and operations professionals.
Clinical Study Status
Patient recruitment is forecast to begin by December 2019, with the aim to enroll up to 400 MDD patients.
The Predict project has received funding from the European Union’s research and Innovation programme under grant agreements No: 808677 & 859051